Skip to main content
OpenTrials
Completed

NCT Number: NCT01221246

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more of the blood vessels supplying the brain) when administered up to 18 hours after symptoms begin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Vascular Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center), Los Angeles, California, United States

Loading trial locations.

About this study

Stroke is a serious and life threatening disease. About 85% of all strokes are ischemic, caused by a blood clot or plaque that blocks a blood vessel in the brain. The thrombolytic drug tissue plasminogen activator (tPA) is the only early treatment for acute ischemic stroke approved by the FDA. Treatment with tPA must be administered within three hours of the stroke onset. Furthermore, tPA treatment carries a recognized risk of bleeding in the brain. GM602 is an investigational drug that may act as a neuroprotectant in patients who have had a stroke. It is thought to stop cell death and reduce inflammation in the injured area of the brain. This study is designed to evaluate the safety and efficacy of GM602 administered intravenously to patients in three consecutive daily doses of 320 mg/dose or 480 mg/dose, the initial dose administered within 18 hours after onset of acute ischemic stroke in the Middle Cerebral artery region.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 18 years old
  • Be eligible for MRI or CT scan
  • Have suffered acute ischemic stroke in the middle cerebral artery (MCA) distribution, as verified by the Screening diffusion-weighted imaging (DWI) abnormality and Screening perfusion-weighted imaging pressure-work index (PWI ) abnormality
  • Have NIH Stroke Scale (NIHSS) score total score of 9-20 inclusive at screening
  • Have suffered acute ischemic stroke within 18 hours
  • Have been functionally independent with a Modified Rankin Score (mRS) of 0 or 1 prior to suffering stroke
  • Patients who received tPA or FDA approved mechanical device can also enroll
  • completed informed consent form

Exclusion criteria

  • Have history of stroke in the past 3 months
  • Cannot be evaluated using MRI/CT
  • Have stroke of the brainstem or cerebellum
  • Have clinical presentation consistent with acute MI by EKG criteria (STEMI) at screening
  • Have hemorrhage revealed by CT or MRI scan
  • Have > 1/3 MCA territory HYPER intensity as seen on MRI OR >1/3 MCA territory HYPO intensity as seen on CT
  • Have blood sugar level >400 mg/DL or<50 mg/dL
  • Have kidney disease, creatinine > 2.0
  • Have had recent (within 90 days) serious head trauma or head trauma with loss of consciousness
  • Have any prior history of seizure
  • Have clinically relevant pre-existing neurological deficit (Historical Rankin score ≥ 2)
  • Have any other known clinically significant medical disorder (cardiovascular, hepatic, renal, endocrine, respiratory, immunological, cancer, AIDS)
  • Life expectancy of less than 6 months due to comorbid conditions
  • Women of child bearing potential who are pregnant or breast-feeding or unable to practice birth control during the study period
  • Have participated in any other trial of an investigational agent within 90 days prior to screening
  • Informed consent cannot be obtained
  • Unable to participate in study visits

Treatment and study plan

GM602

Drug

First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.

Other names: GM6, GM604, GM608, MNTF

placebo comparator

Drug

First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.

Other names: Bacteriostatic saline

Primary outcomes

  1. Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint

    Time frame: Day 90

    NIH Stroke Scale is a standardized neurological examination intended to describe the neurological deficits found in large groups of stroke patients participating in treatment trials. Percent change from baseline in NIHSS is calculated and compared.

Secondary outcomes

  1. Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo

    Time frame: Day 30

    Percent change in NIHSS from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo

  2. Percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo

    Time frame: Day 90

    The Barthel Index is measured using both historical and direct observational information. It measures self-care and mobility and will help define the degree of residual disability. Percent change from baseline in BI is calculated.

  3. Percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo

    Time frame: Day 30

    Percent change in BI from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo

  4. Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days

    Time frame: Day 90

    compared with placebo at each modified Rankin Scale (mRS) level at 90 days.

  5. Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days

    Time frame: Day 30

    compared with placebo at each modified Rankin Scale (mRS) level at 30 days.

  6. Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo

    Time frame: Day 90

    all cause mortality data through 3 months

Other outcomes

  1. Primary Safety Endpoints

    Time frame: througyh 3 months

    Adverse events, Fatal intracranial hemorrhage (ICH). nonfatal symptomatic parenchymal hemorrhage, or other symptomatic ICH, Neurological deterioration during hospitalization, Number of seizures after stroke, Respiratory compromise as observed by respiratory rate

Sponsors and collaborators

Lead sponsor

Genervon Biopharmaceuticals, LLC

Industry

Collaborators

  • California Pacific Medical Center Research Institute
  • Columbia University
  • Hoag Memorial Hospital Presbyterian
  • Huntington Hospital
  • Sarasota Memorial Hospital
  • University Hospital Erlangen
  • University of California, Los Angeles
  • University of Louisville

Registry information

Official study title

A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window

Acronym: GMAIS

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Oct 14, 2010
Registry last updated
Aug 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.